Achmea Investment Management B.V. Incyte Corp Transaction History

Achmea Investment Management B.V.

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 24, 2023	SELL	$60.95 - $75.51 $25,233 - $31,261	-414 Reduced 2.12%	19,115 $1.19 Million
Q1 2023 May 04, 2023	BUY	$70.23 - $86.01 $235,059 - $287,875	3,347 Added 20.68%	19,529 $1.41 Million
Q4 2022 Feb 09, 2023	BUY	$67.18 - $84.11 $47,026 - $58,877	700 Added 4.52%	16,182 $1.22 Million
Q3 2022 Oct 27, 2022	SELL	$66.18 - $82.86 $123,624 - $154,782	-1,868 Reduced 10.77%	15,482 $1.03 Million
Q2 2022 Aug 10, 2022	BUY	$66.18 - $83.18 $77,165 - $96,987	1,166 Added 7.2%	17,350 $1.32 Million
Q1 2022 May 16, 2022	BUY	$66.02 - $79.71 $289,893 - $350,006	4,391 Added 37.23%	16,184 $1.29 Million
Q3 2021 Nov 12, 2021	BUY	$68.67 - $84.02 $809,825 - $990,847	11,793 New	11,793 $811,000
Q4 2020 Feb 22, 2021	SELL	$80.74 - $97.7 $609,506 - $737,537	-7,549 Closed	0 $0
Q3 2020 Nov 02, 2020	SELL	$85.07 - $109.69 $759,504 - $979,312	-8,928 Reduced 54.18%	7,549 $678,000
Q1 2020 May 13, 2020	BUY	$63.18 - $85.97 $564,071 - $767,540	8,928 Added 118.27%	16,477 $1.21 Million
Q2 2019 Aug 06, 2019	SELL	$73.52 - $88.7 $136,379 - $164,538	-1,855 Reduced 19.73%	7,549 $641,000
Q1 2019 May 15, 2019	BUY	$63.56 - $88.17 $479,814 - $665,595	7,549 Added 406.95%	9,404 $809,000
Q3 2018 Nov 06, 2018	SELL	$61.75 - $74.23 $197,167 - $237,016	-3,193 Reduced 63.25%	1,855 $128,000
Q4 2017 Feb 12, 2018	SELL	$93.56 - $116.6 $551,349 - $687,123	-5,893 Reduced 53.86%	5,048 $478,000
Q3 2017 Nov 09, 2017	BUY	$109.15 - $138.27 $550,989 - $697,986	5,048 Added 85.66%	10,941 $1.28 Million
Q2 2017 Aug 29, 2017	BUY	N/A	5,893	5,893 $741,000

645

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.3B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Achmea Investment Management B.V., based on Form 13F filings with the SEC.

Stay updated on Achmea Investment Management B.V. with notifications on news.